pf-06826647
Small moleculeexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jul 14, 2017 (NCT03210961)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase TYK2INHIBITOR
TYK2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04591262 | Phase 1 | Nov 10, 2020 | Pfizer |
| NCT04209556 | Phase 2 | Jan 24, 2020 | Pfizer |
| NCT04092452 | Phase 2 | Nov 11, 2019 | Pfizer |
| NCT04134715 | Phase 1 | Oct 15, 2019 | Pfizer |
| NCT03895372 | Phase 2 | Jul 31, 2019 | Pfizer |
| NCT03210961 | Phase 1 | Jul 14, 2017 | Anaheim Clinical Trials, Pfizer |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 6 | 6 | 2 | 2017 |
| Anaheim Clinical Trials | For profit | 1 | 0 | 1 | 2017 |
2 organizations
Page 1 / 1